Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
(NYSE MKT:SER), Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson's under the 505(b)(2) NDA pathway Evaluating complementary funding including strategic equity and non-dilutive alternatives HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary […]